ERK2, but Not ERK1, Mediates Acquired and “ De novo ” Resistance to Imatinib Mesylate: Implication for CML Therapy

Clara I. Aceves-Luquero, Anupriya Agarwal, Juan L. Callejas-Valera et al. · 2009

Read ERK2, but Not ERK1, Mediates Acquired and “ De novo ” Resistance to Imatinib Mesylate: Implication for CML Therapy by Clara I. Aceves-Luquero, Anupriya Agarwal, Juan L. Callejas-Valera et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0006124.txt.

Description

Leukemia cells learn to shrug off the drug that once controlled them. Clara Aceves-Luquero, Anupriya Agarwal, Juan Callejas-Valera and colleagues found a driver of that resistance in 2009. Their PLOS ONE paper studies imatinib mesylate resistance in chronic myelogenous leukaemia, beyond the well-known route of mutations in the drug's target, BCR/ABL.

ERK2, but not its close sibling ERK1, mediates both acquired and de novo resistance, the title reports. Splitting two near-identical kinases matters, because a drug can then block one and spare the other. The result gives CML therapy a concrete second target for cases where imatinib alone stops working.

Catalog record

CREATORClara I. Aceves-Luquero, Anupriya Agarwal, Juan L. Callejas-Valera et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0006124

Browse the full library · About the Tower of Babel